Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
IMNP On Other Exchanges
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

immune pharmaceuticals inc (IMNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/22/14 - $3.28
52 Week Low
10/1/15 - $0.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immune pharmaceuticals inc (IMNP) Related Bloomberg News

View More Bloomberg News

immune pharmaceuticals inc (IMNP) Related Businessweek News

No Related Businessweek News Found

immune pharmaceuticals inc (IMNP) Details

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes targeted therapeutics for the treatment of inflammatory diseases and cancer. The company’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is under Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies; NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is under Phase I/II clinical trials for the treatment of patients with solid tumors. The company has license, and other collaborative research and development arrangements with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Lonza Sales AG; Dalhousie University; Shire Biochem, Inc.; and Endo Pharmaceuticals. The company was founded in 2010 and is headquartered in New York, New York.

9 Employees
Last Reported Date: 04/15/15
Founded in 2010

immune pharmaceuticals inc (IMNP) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2014.

immune pharmaceuticals inc (IMNP) Key Developments

Immune Pharmaceuticals wins USD 3 Million in Second Tranche Under Financing Agreement with Discover Growth Fund

Immune Pharmaceuticals, Inc. reported that it has received another USD 3 million in gross proceeds from Discover Growth Fund from a previous financing agreement. This second tranche is in addition to the prior gross proceeds of USD 9 million from Discover at the same USD 2.50 conversion price plus the USD 4.5 million from Hercules Technology Growth Capital.

Immune Pharmaceuticals Receives Second Tranche of $3 Million from Discover Growth Fund

Immune Pharmaceuticals, Inc. announced that Immune has received an additional $3 million in gross proceeds from Discover Growth Fund pursuant to the agreement previously disclosed in the Company's Current Report on Form 8K filed on July 29, 2015. This financing was in addition to the gross proceeds of $9 million already received from Discover at the same $2.50 conversion price and terms and the $4.5 million from Hercules Technology Growth Capital. Hercules also provided Immune the option to draw down additional capital under the term loan of up to $5 million in gross proceeds subject to clinical milestones and other conditions. The additional $3 million from Discover was received upon an effective "resale" registration statement pertaining to the Series D Preferred and stockholders approval on September 25, 2015.

Immune Pharmaceuticals, Inc. Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 through Sep-30-2015

Immune Pharmaceuticals, Inc. Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 through Sep-30-2015. Venue: Congress Center, Basel, Switzerland. Presentation Date & Speakers: Sep-29-2015, Celia Zinger, Director Medical Affairs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMNP:US $1.20 USD 0.00

IMNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $1.99 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation IMNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at